You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Potent DYRK1B inhibitor (IC50 values are 17, 88 and 1890 nM for DYRK1B, DYRK1A and DYRK2 respectively). Inhibits DYRK1B-induced Gi phase cell cycle arrest in Panc-1 cells in vitro.
External Portal Information
Chemicalprobes.org is a portal that offers independent guidance on the selection and/or application of small molecules for research. The use of AZ 191 is reviewed on the chemical probes website.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 429.52. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.33 mL||11.64 mL||23.28 mL|
|5 mM||0.47 mL||2.33 mL||4.66 mL|
|10 mM||0.23 mL||1.16 mL||2.33 mL|
|50 mM||0.05 mL||0.23 mL||0.47 mL|
References are publications that support the biological activity of the product.
Ashford et al (2014) A novel DYRK1B inhibitor AZ191 demonstrates that DYRK1B acts independently of GSK3 beta to phosphorylate cyclin D1 at Thr(286), not Thr(288). Biochem.J. 457 43 PMID: 24134204
If you know of a relevant reference for AZ 191, please let us know.
View Related Products by Product Action
Keywords: AZ 191, AZ 191 supplier, AZ191, potent, dyrk1b, dual, specificity, tyrosine, phosphorylation, regulated, kinases, inhibitors, inhibits, DYRK, 5232, Tocris Bioscience
1 Citation for AZ 191
Citations are publications that use Tocris products. Selected citations for AZ 191 include:
Blake et al (2019) Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer. Sci Signal 12 PMID: 31311847
Do you know of a great paper that uses AZ 191 from Tocris? Please let us know.
Reviews for AZ 191
There are currently no reviews for this product. Be the first to review AZ 191 and earn rewards!
Have you used AZ 191?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.